Stock Market

HealthEquity (HQY) Stock Looks Like A Bargain Despite A 54% Run


HealthEquity has delivered a solid 53.8% share price gain over the past five years, yet the real question for investors is how well that move lines up with the cash the business is expected to generate. With the stock changing hands at around US$97.31 after some mixed shorter term returns, the focus naturally shifts to whether its cash flows can support that kind of valuation.

  • A 53.8% return over five years puts meaningful expectations into the price, which raises the stakes for whether HealthEquity’s future cash generation can keep pace.

  • The company runs a fee and asset based model tied to health savings accounts, which can influence both the level and timing of cash inflows as balances and engagement change over time.

  • Prefer to judge HealthEquity on earnings? See why HealthEquity’s 34.0x P/E tells a different valuation story.

The issue now is whether HealthEquity’s current share price is well aligned with what its cash flows suggest when valued using a Discounted Cash Flow (DCF) approach.

If you want to test the same cash flow question beyond HealthEquity, you can compare it with other companies using the 35 high quality undervalued stocks

Is HealthEquity a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach values HealthEquity by tying its share price back to the cash it can return to shareholders over time. On this view, the group produced last twelve month free cash flow of about $266.3 million, with the model assuming that annual cash generation grows rather than contracts from here.

Analyst forecasts used in the DCF see free cash flow moving into the $500 million range within a few years, then rising more gradually as the business matures. When those future streams are discounted back and compared with today’s traded level of US$97.31, the DCF projections put HealthEquity’s estimated intrinsic value substantially above the current share price. Find out what HealthEquity could be worth using our Discounted Cash Flow (DCF) estimate.

The HealthEquity Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives pick up where the DCF puzzle for HealthEquity leaves off and spell out what kind of growth path, profitability profile and earnings power would need to show up in the actual results for the share price to look meaningfully higher or lower than it does today. Each storyline links its number to a specific view on how HealthEquity’s growth, margins and risk profile might evolve. This gives you something concrete to revisit as fresh information comes through on the Community page.

One of the top narratives on HealthEquity: 18% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts’ consensus price target and revenue and earnings forecasts, not one person’s view.

“The current valuation implies the market is not fully pricing in HealthEquity’s guidance for higher adjusted EBITDA, visibility into HSA cash yields and sizeable share repurchases…”

Discover why this Narrative puts HealthEquity at 18% undervalued.

One more question on HealthEquity that could change the picture

Before moving on from HealthEquity, it is worth asking who is actually steering the ship and how their rewards line up with long term outcomes for shareholders. See who runs HealthEquity and how they are paid.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HQY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



Source link

Leave a Response